Table 1.
Expression of short‐chain O‐GalNAC glycans in bladder tumours of different clinicopathological natures determined by immunohistochemistry
| Tn | STn | T | ST | S6T | S3T | ||
|---|---|---|---|---|---|---|---|
| Non‐muscle invasive bladder cancer (NMIBC) (%) | |||||||
| Low Grade | 17 | ||||||
| − | 15 (88) | 13 (76) | 13 (76) | 0 (0) | 2 (12) | 10 (59) | |
| + | 2 (12) | 4 (24) | 4 (24) | 5 (29) | 11 (65) | 6 (35) | |
| ++ | 10 (59) | 4 (24) | 1 (6) | ||||
| +++ | 2 (12) | ||||||
| ++++ | |||||||
| Positive cases, n (%) | 2 (12) | 4 (24) | 4 (24) | 17 (100) | 15 (89) | 7 (41) | |
| High Grade | 12 | ||||||
| − | 5 (42) | 3 (25) | 9 (75) | 0 (0) | 0 (0) | 3 (29) | |
| + | 7 (58) | 7 (58) | 3 (25) | 3 (25) | 5 (42) | 7 (57) | |
| ++ | 2 (17) | 2 (17) | 7 (58) | 2 (14) | |||
| +++ | 7 (58) | ||||||
| ++++ | |||||||
| Positive cases, n (%) | 7 (58) | 9 (75) | 3 (25) | 12 (100) | 12 (100) | 9 (71) | |
| Muscle invasive bladder cancer (MIBC) | |||||||
| 18 | |||||||
| − | 16 (89) | 2 (11) | 0 (0) | 0 (0) | 5 (28) | 7 (39) | |
| + | 2 (11) | 16 (89) | 4 (22) | 3 (17) | 8 (44) | 7 (39) | |
| ++ | 6 (33) | 5 (28) | 6 (33) | 4 (22) | |||
| +++ | 5 (28) | 6 (33) | |||||
| ++++ | 3 (16) | 4 (22) | |||||
| Positive cases, n (%) | 2 (11) | 16 (89) | 18 (100) | 18 (100) | 14 (78) | 11 (61) | |
| Total positive cases | 47 | 11 (23) | 13 (62) | 25 (53) | 47 (100) | 38 (81) | 27 (57) |
Scoring: −, negative; +: > 0–19%; ++: 20–49%; +++: 50–79%; ++++: ≥ 80%.